TNFSF10 and neoplasm: Owing to the large number of events that can affect TRAIL’s efficacy, combined treatments associating cytotoxic drugs and TRAIL or TRAIL variants have emerged to restore TRAIL sensitivity in resistant tumor cells [24,64,65,66,67,68,69,70,71,72,73].